Activity of once-daily cefpodoxime regimens against Haemophilus influenzae and Streptococcus pneumoniae with an in vitro pharmacodynamic chamber model

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 6, 1996, Pages 1545-1547

  Garrison, Mark W ^a,b   Malone, Connie L ^a,b   Eiland, John E ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Deaconess Medical Center Spokane   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFPODOXIME;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; GRAM NEGATIVE INFECTION; GROWTH INHIBITION; HAEMOPHILUS INFLUENZAE; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 0029893310     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.6.1545     Document Type: Article

References (19)

1. Asmar, B. I., A. S. Dajani, M. A. Del-Beccaro, and P. M. Mendelman. 1994. Comparison of cefpodoxime proxetil and cefixime in the treatment of acute otitis media in infants and children. Pediatrics 94(6 Pt. 1):847-852.
2. Bergogne-Berezin, E. 1991. Cefpodoxime proxetil in upper respiratory tract infections. Drugs 42(Suppl 3):25-33.
3. Borin, M. T. 1991 A review of the pharmacokinetics of cefpodoxime proxetil. Drugs 42(Suppl. 3):13-21.
4. Chapin-Robertson, K., and S. C. Edberg. 1991. Measurement of antibiotics in human body fluids: techniques and significance, p. 313. In V. Lorian (ed), Antibiotics in laboratory medicine, 3rd ed. The Williams & Wilkins Co., Baltimore
5. Chocas, E. C., C. M. Paap, and P. J. Godley. 1993. Cefpodoxime proxetil: a new, broad-spectrum, oral cephalosporin. Ann Pharmacother. 27:1369-1377.
6. Craig, W. A., and D. R. Andes. 1995. Parenteral versus oral antibiotic therapy. Med Clin. N Am 79:497-508.
7. Dabernat, H., J. L. Avril, and Y. Boussougant. 1990. In vitro activity of cefpodoxime against pathogens responsible for community-acquired respiratory tract infections. J. Antimicrob Chemother. 26(Suppl E):1-6.
8. Ebert, S. C., and W. A. Craig. 1990 Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design. Infect Control Hosp. Epidemiol. 11:319-326.
9. Frampton, J. E., R. N. Brogden, H. D. Langtry, and M. M. Buckley. 1992. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 44:889-917
10. Fung-tomc, J. C., E. Huczko, T. Stickle, B. Minassian, B. Kolek, K. Denbleyker, D. Bonner, and R. Kessler. 1995. Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides Antimicrob. Agents Chemother. 39:533-538.
11. Garrison, M. W., D. M. Campbell, D. A. Selar, and D. E. Anderson. 1994. Comparative activity of temafloxacin, ofloxacin and ciprofloxacin against Streptococcus pneumoniae using an in vitro pharmacodynamic model apparatus. Curr. Ther. Res. 55:1432-1441.
12. Garrison, M. W., K. Vance-Bryan, T. A. Larson, J. P. Toscano, and J. C. Rotschafer. 1990. Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 34:1925-1931.
13. Geddes, A. M. 1991. Cefpodoxime proxetil in the treatment of lower respiratory tract infections Drugs 42(Suppl. 3):34-40.
14. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. Document M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
15. Nicolau, D. P., K. Quintiliani, and C. H. Nightingale. 1995. Antibiotic kinetics and dynamics for the clinician. Med. Clin N. Am. 79:477-495.
16. Rodman, D. P., J. T. McKnight, and R. L. Anderson. 1994. A critical review of the new oral cephalosporins. Considerations and place in therapy. Arch. Fam. Med. 3:975-980.
17. Schentag, J. J., D. E. Nix, and M. H. Adelman. 1991 Mathematical examination of dual individualization principles. I. Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP Ann Pharmacother. 25:1050-1057.
18. Vogelman, B., S. Gundmundsson, J. Legget, J. Turnidge, S. Ebert, and W. A. Craig. 1988. Correlation of antimicrobial pharmacokinetic parameters with efficacy in an animal model. J. Infect Dis. 158:831-847.
19. Yagi, B. H., R. D. Schaadt, and G. E. Zurenko. 1991. The postantibiotic effect of cefpodoxime and cefixime using the Abbott ADVANTAGE system, abstr. 142, p. 122. In Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.